<div id="readability-page-1"><div><h2>Recent share performance and business snapshot</h2> <p>Ascentage Pharma Group International (SEHK:6855) has drawn investor attention after recent share price moves, with returns of about 13% over the past week and 15% over the past month.</p> <p>The Suzhou based clinical stage biotech focuses on therapies for cancers, chronic hepatitis B and age related diseases in Mainland China. It generated HK$574.12 million in revenue and reported a net loss of HK$1,242.77 million.</p> <p>See our latest analysis for Ascentage Pharma Group International.</p> <p>While the recent 13.2% 7-day share price return and 15.0% 30-day share price return hint at improving momentum from HK$52.05, the 6.8% 90-day share price decline contrasts with a much stronger 50.2% 1-year total shareholder return. This suggests sentiment has warmed over a longer horizon.</p> <p>If you are looking beyond a single biotech name, this could be a good moment to scan opportunities across 127 healthcare AI stocks.</p> <p>With the shares sitting at HK$52.05 and trading at a sizeable discount to a HK$96.40 target and intrinsic value estimates, you have to ask: is this a mispriced growth story, or is the market already looking ahead?</p> <h2>Most Popular Narrative: 42.9% Undervalued</h2> <p>With Ascentage Pharma Group International last closing at HK$52.05 versus a narrative fair value of HK$91.17, the current price sits well below that framework.</p> <blockquote> <p><em>The company remains fundamentally vulnerable due to its heavy reliance on a development-stage pipeline in highly competitive oncology segments, where clinical failure or regulatory delay, compounded by industry-wide scrutiny of trial design, could halt new product launches and trigger significant drops in projected revenue and net margins.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Want to see what justifies such a large gap between price and fair value? The narrative leans on brisk revenue expansion, rising margins, and a rich future earnings multiple. Curious which specific assumptions drive that HK$91.17 figure and how sensitive it is to execution on the late stage pipeline?</p> <p><strong>Result: Fair Value of HK$91.17 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, there are still important risks, including reliance on a development stage pipeline and potential pressure on drug pricing in China, that could challenge this upbeat narrative.</p> <p>Find out about the key risks to this Ascentage Pharma Group International narrative.</p> <h2>Another angle on valuation</h2> <p>The narrative fair value of HK$91.17 frames Ascentage Pharma Group International as undervalued, yet the current P/S of 29.3x is much richer than the Hong Kong Biotechs industry at 13.7x, the peer average at 13x, and even the 17.5x fair ratio that the market could move toward. Could that premium compress faster than the story plays out?</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d52fef21-5fae-4cef-b9b4-ab4bbcc4ee34/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA0LTA4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d52fef21-5fae-4cef-b9b4-ab4bbcc4ee34/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA0LTA4"/><figcaption>SEHK:6855 P/S Ratio as at Apr 2026</figcaption></figure><h2>Next Steps</h2> <p>If the mix of optimism and caution in this story leaves you undecided, now is a good time to review the details yourself and see what stands out in the data. Then weigh those findings against the 2 key rewards</p> <h2>Looking for more investment ideas?</h2> <p>If you are still weighing up Ascentage Pharma Group International, this is the moment to broaden your watchlist and uncover other opportunities that could fit your goals.</p> <ul> <li>Spot potential turnaround stories early by scanning 229 elite penny stocks with strong financials before they attract wider attention.</li> <li>Zero in on quality at a discount by reviewing the 241 high quality undervalued stocks that may offer more appealing entry points.</li> <li>Strengthen the defensive side of your portfolio by checking the 286 resilient stocks with low risk scores that focus on resilience when conditions change.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

520690

159316

159570

<p>Ascentage Pharma Group International (SEHK:6855) has seen a 13% rise in share price over the past week and 15% over the past month, despite a 6.8% decline over 90 days. The company reported HK$574.12 million in revenue but a net loss of HK$1,242.77 million. Current share price is HK$52.05, significantly below the fair value estimate of HK$91.17, indicating it may be undervalued. However, risks include reliance on a development-stage pipeline and potential pricing pressures in China. Investors are encouraged to explore other opportunities in the healthcare sector.</p>

Simplywall

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

ASCENTAGE-B

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Assessing Ascentage Pharma Group International’s Valuation After Recent Share Price Momentum